Compounds > sk&f 81297
Page last updated: 2024-10-21

sk&f 81297 and Basal Ganglia Diseases

sk&f 81297 has been researched along with Basal Ganglia Diseases in 1 studies

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lublin, H1
Gerlach, J1
Mørkeberg, F1

Other Studies

1 other study available for sk&f 81297 and Basal Ganglia Diseases

ArticleYear
Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
    Psychopharmacology, 1994, Volume: 114, Issue:3

    Topics: Animals; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Benzofurans; Cebus; Dopamine Agonis

1994